Arrowhead Pharmaceuticals, Inc. $ARWR Stock Position Reduced by WINTON GROUP Ltd

Key Points

• WINTON GROUP Ltd cut its Arrowhead Pharmaceuticals position by 82.5% in the second quarter, selling 45,450 shares and retaining 9,630 shares worth approximately $785,000.
• Institutional ownership remains substantial at 62.61%, with BlackRock initiating a major position and California State Teachers Retirement System increasing its stake by 7,797.6%.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $99.15, although Arrowhead recently missed quarterly EPS estimates and continues to report negative profitability.

WINTON GROUP Ltd decreased its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 9,630 shares of the biotechnology company's stock after selling 45,450 shares during the quarter. WINTON GROUP Ltd's holdings in Arrowhead Pharmaceuticals were worth $785,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in ARWR. BlackRock Inc. bought a new position in Arrowhead Pharmaceuticals during the second quarter worth $1,208,838,000. California State Teachers Retirement System increased its stake in Arrowhead Pharmaceuticals by 7,797.6% during the second quarter. California State Teachers Retirement System now owns 11,397,217 shares of the biotechnology company's stock valued at $928,987,000 after purchasing an additional 11,252,904 shares during the last quarter. Geode Capital Management LLC increased its stake in Arrowhead Pharmaceuticals by 4.3% during the fourth quarter. Geode Capital Management LLC now owns 3,264,963 shares of the biotechnology company's stock valued at $216,799,000 after purchasing an additional 133,921 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in shares of Arrowhead Pharmaceuticals by 30.2% during the fourth quarter. Baker BROS. Advisors LP now owns 2,175,645 shares of the biotechnology company's stock worth $144,441,000 after purchasing an additional 504,883 shares during the period. Finally, Arrowstreet Capital Limited Partnership raised its holdings in shares of Arrowhead Pharmaceuticals by 0.3% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,087,953 shares of the biotechnology company's stock worth $138,619,000 after purchasing an additional 6,264 shares during the period. 62.61% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on ARWR. JPMorgan Chase & Co. lifted their price target on shares of Arrowhead Pharmaceuticals from $88.00 to $95.00 and gave the company an "overweight" rating in a report on Friday, July 17th. Stifel Nicolaus assumed coverage on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, July 14th. They set a "buy" rating and a $98.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $120.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 1st. B. Riley Financial lifted their target price on Arrowhead Pharmaceuticals from $101.00 to $123.00 and gave the company a "buy" rating in a research note on Thursday, July 30th. Finally, Leerink Partners upped their target price on Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the company a "market perform" rating in a report on Wednesday, June 17th. Ten investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $99.15.

Insider Buying and Selling

In related news, Director Michael Perry sold 11,600 shares of the stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $87.30, for a total value of $1,012,680.00. Following the completion of the transaction, the director directly owned 111,459 shares of the company's stock, valued at $9,730,370.70. This represents a 9.43% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Adeoye Olukotun sold 2,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the sale, the director directly owned 31,600 shares in the company, valued at $2,747,936. The trade was a 5.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Corporate insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Trading Down 2.6%

Shares of NASDAQ:ARWR opened at $80.67 on Tuesday. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The company's 50-day moving average price is $84.18 and its 200 day moving average price is $75.22. The company has a market cap of $11.36 billion, a PE ratio of -35.85 and a beta of 1.28. Arrowhead Pharmaceuticals, Inc. has a fifty-two week low of $28.12 and a fifty-two week high of $95.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.13). The firm had revenue of $75.25 million during the quarter, compared to the consensus estimate of $44.17 million. Arrowhead Pharmaceuticals had a negative return on equity of 60.06% and a negative net margin of 47.79%.Arrowhead Pharmaceuticals's revenue for the quarter was up 171.0% on a year-over-year basis. During the same quarter last year, the company posted ($1.26) EPS. Sell-side analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc NASDAQ: ARWR is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to target conditions that may be difficult to treat with conventional drugs.

Arrowhead's proprietary TRiM platform is designed to deliver RNAi-based therapies to different tissues, including the liver, lungs and other organs. Its investigational pipeline has included candidates for cardiovascular and metabolic diseases, liver disorders, pulmonary conditions and inflammatory diseases.

Want to see what other hedge funds are holding ARWR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.